Impaired Consciousness and Decreased Glucose Concentration of CSF As Prognostic Factors in Immunocompetent Patients with Cryptococcal Meningitis

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2020 Jan 24

PMID 31969152

Citations 9

Authors

Chen Zhang

Zheren Tan

Fafa Tian

Affiliations

Soon will be listed here.

Abstract

Background: Cryptococcal meningitis (CM) is the most common fungal infection of the central nervous system and has high morbidity and mortality. Almost studies about prognostic factors have largely focused on the immunocompromised population rather than immunocompetent patients. So that we sought to conduct a retrospective study to determine prognostic factors which predict the outcomes in immunocompetent patients with CM.

Methods: We retrospectively collected and analyzed the demographic and clinical data of 76 apparently immunocompetent patients with cryptococcal meningitis from January 2003 to June 2019 in China. The clinical outcome was graded by the Glasgow outcome scale (GOS) at discharge, and patients were divided into good (score of 5) and unfavorable (score of 1-4) outcome groups, potential prognostic factors were analyzed.

Results: Non-parametric test confirmed that unfavorable outcome was associated with lower glucose level of CSF(P = 0.001), and Pearson's χ2 analysis confirmed that unfavorable outcome was associated with opening pressure of CSF(>300mmH20, P = 0.038), impaired consciousness (P = 0.001), hydrocephalus(P = 0.045), and Shunt surgery (P = 0.045), and then multiple logistic regression analysis confirmed that impaired consciousness(P = 0.015) and lower glucose concentration of CSF(P = 0.012) increased the likelihood of unfavorable outcome in CM patients.

Conclusion: Impaired consciousness and decreased glucose concentration of CSF were independently prognostic factors which predict the unsatisfactory outcome in immunocompetent patients with CM.

Citing Articles

A Novel Diagnostic Prediction Model for Distinguishing Between Tuberculous and Cryptococcal Meningitis.

Niu M, Bai Z, Dong L, Zheng W, Wang X, Dong N Clin Med Res. 2025; 22(4):197-205.

PMID: 39993828 PMC: 11849970. DOI: 10.3121/cmr.2024.1869.

A Retrospective Analysis of Central and Peripheral Metabolic Characteristics in Patients with Cryptococcal Meningitis.

Qin J, Nong L, Zhu Q, Huang Z, Wu F, Li S Neurol Ther. 2024; 13(3):763-784.

PMID: 38643256 PMC: 11136911. DOI: 10.1007/s40120-024-00610-z.

Construction and validation of a nomogram model to predict the poor prognosis in patients with pulmonary cryptococcosis.

Tan X, Zhang Y, Zhou J, Chen W, Zhou H PeerJ. 2024; 12:e17030.

PMID: 38487258 PMC: 10939030. DOI: 10.7717/peerj.17030.

Cerebrospinal fluid shunting for the management of cryptococcal meningitis: a scoping review.

Cornejo-Venegas G, Carreras X, Salcedo A, Soriano-Moreno D, Salinas J, Alave J Ther Adv Infect Dis. 2024; 11:20499361241228666.

PMID: 38333229 PMC: 10851763. DOI: 10.1177/20499361241228666.

Development and validation of a machine learning model to predict prognosis in HIV-negative cryptococcal meningitis patients: a multicenter study.

Liu J, Lu Y, Liu J, Liang J, Zhang Q, Li H Eur J Clin Microbiol Infect Dis. 2023; 42(10):1183-1194.

PMID: 37606868 DOI: 10.1007/s10096-023-04653-2.

References

Lagrou K, Van Eldere J, Keuleers S, Hagen F, Merckx R, Verhaegen J . Zoonotic transmission of Cryptococcus neoformans from a magpie to an immunocompetent patient. J Intern Med. 2005; 257(4):385-8. DOI: 10.1111/j.1365-2796.2005.01466.x. View

Lu C, Chang W, Chang H, Chuang Y . The prognostic factors of cryptococcal meningitis in HIV-negative patients. J Hosp Infect. 1999; 42(4):313-20. DOI: 10.1053/jhin.1998.0610. View

Agha Kuchak Afshari S, Shokohi T, Aghili R, Badali H . Epidemiology and molecular characterization of Cryptococcus neoformans isolated from pigeon excreta in Mazandaran province, northern Iran. J Mycol Med. 2013; 22(2):160-6. DOI: 10.1016/j.mycmed.2012.02.002. View

Lui G, Lee N, Ip M, Choi K, Tso Y, Lam E . Cryptococcosis in apparently immunocompetent patients. QJM. 2006; 99(3):143-51. DOI: 10.1093/qjmed/hcl014. View

Ecevit I, Clancy C, Schmalfuss I, Nguyen M . The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin Infect Dis. 2006; 42(10):1443-7. DOI: 10.1086/503570. View

Shih C, Chen Y, Chang S, Luh K, Hsieh W . Cryptococcal meningitis in non-HIV-infected patients. QJM. 2000; 93(4):245-51. DOI: 10.1093/qjmed/93.4.245. View

Hagen F, Lumbsch H, Arsic Arsenijevic V, Badali H, Bertout S, Billmyre R . Importance of Resolving Fungal Nomenclature: the Case of Multiple Pathogenic Species in the Genus. mSphere. 2017; 2(4). PMC: 5577652. DOI: 10.1128/mSphere.00238-17. View

Tan Z, Long X, Li G, Zhou J, Long L . Spectrum of neuroimaging findings in cryptococcal meningitis in immunocompetent patients in China - A series of 18 cases. J Neurol Sci. 2016; 368:132-7. DOI: 10.1016/j.jns.2016.06.069. View

Vidal J, Gerhardt J, Peixoto de Miranda E, Dauar R, Oliveira Filho G, de Oliveira A . Role of quantitative CSF microscopy to predict culture status and outcome in HIV-associated cryptococcal meningitis in a Brazilian cohort. Diagn Microbiol Infect Dis. 2012; 73(1):68-73. PMC: 3351690. DOI: 10.1016/j.diagmicrobio.2012.01.014. View

10.

Henao-Martinez A, Chastain D, Franco-Paredes C . Treatment of cryptococcosis in non-HIV immunocompromised patients. Curr Opin Infect Dis. 2018; 31(4):278-285. DOI: 10.1097/QCO.0000000000000458. View

11.

Yuchong C, Fubin C, Jianghan C, Fenglian W, Nan X, Minghui Y . Cryptococcosis in China (1985-2010): review of cases from Chinese database. Mycopathologia. 2011; 173(5-6):329-35. DOI: 10.1007/s11046-011-9471-1. View

12.

Hung C, Chang W, Kung C, Tsai N, Wang H, Lin W . Predictors and long-term outcome of seizures in human immuno-deficiency virus (HIV)-negative cryptococcal meningitis. BMC Neurol. 2014; 14:208. PMC: 4203868. DOI: 10.1186/s12883-014-0208-x. View

13.

Bandalizadeh Z, Shokohi T, Badali H, Abastabar M, Babamahmoudi F, Davoodi L . Molecular epidemiology and antifungal susceptibility profiles of clinical species complex. J Med Microbiol. 2019; 69(1):72-81. PMC: 7137767. DOI: 10.1099/jmm.0.001101. View

14.

Saag M, Graybill R, Larsen R, Pappas P, Perfect J, Powderly W . Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000; 30(4):710-8. DOI: 10.1086/313757. View

15.

Yao Z, Liao W, Chen R . Management of cryptococcosis in non-HIV-related patients. Med Mycol. 2005; 43(3):245-51. DOI: 10.1080/13693780410001731628. View

16.

Liao C, Chi C, Wang Y, Tseng S, Chou C, Ho C . Different presentations and outcomes between HIV-infected and HIV-uninfected patients with Cryptococcal meningitis. J Microbiol Immunol Infect. 2012; 45(4):296-304. DOI: 10.1016/j.jmii.2011.12.005. View

17.

Liliang P, Liang C, Chang W, Chen H, Su T, Lu K . Shunt surgery for hydrocephalus complicating cryptococcal meningitis in human immunodeficiency virus-negative patients. Clin Infect Dis. 2003; 37(5):673-8. DOI: 10.1086/377208. View

18.

Saag M, Powderly W, Cloud G, Robinson P, GRIECO M, Sharkey P . Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992; 326(2):83-9. DOI: 10.1056/NEJM199201093260202. View

19.

Li M, Chen Z, Xu L, Gan Z, Peng F, Liu J . A Comparison of the Clinical Characteristics and Outcomes of Cryptococcal Meningitis in HIV-negative Individuals With and Without Immunosuppression. Neurologist. 2018; 24(1):1-5. DOI: 10.1097/NRL.0000000000000221. View

20.

Badali H, Alian S, Fakhim H, Falahatinejad M, Moradi A, Davoudi M . Cryptococcal meningitis due to Cryptococcus neoformans genotype AFLP1/VNI in Iran: a review of the literature. Mycoses. 2015; 58(12):689-93. DOI: 10.1111/myc.12415. View